Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Fakharian, 2021 IRCT20151227025726N2

adalimumab (n=34) vs. standard of care (n=34)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Adalimumab
Standard of care plus adalimumab 40mg single dose subcutaneously.

Control treatment

Standard of care
SoC only.

Both groups received oxygen and fluid support, remdesivir 200 mg stat followed by 100 mg intravenously daily for five to ten days, and dexamethasone 6 mg intravenously daily for ten days or up to the point of discharge.

Patients

COVID-19 severe or critically

Method

Open-label.

Dr. Masih, Daneshvari Hospital, Tehran, Iran.

Remark